Orchard Therapeutics Announces Second Closing of Strategic Financing, Resulting in $34 Million of Additional Capital

Orchard Therapeutics has raised $34 million in new capital from the second closing of a securities purchase agreement, extending its cash runway through to mid-2025. The funding will support the advancement of its hematopoietic stem cell (HSC) gene therapy portfolio and preparations for the US launch of OTL-200 for MLD, pending FDA approval. The company expects that this funding will provide imp..